www.praktickelekarenstvi.cz e19 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Postavení pioglitazonu v moderní léčbě diabetes mellitus 2. typu myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infar‑ ction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol. 2007;49:1772-1780. 21. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglita‑ zone clinical trial in macrovascular events 04). Stroke. 2007;38:865-873. 22. Young LH, Viscoli CM, Inzucchi SE, et al. Cardiac outcomes after ischemic stroke or tran‑ sient ischemic attack: effects of pioglitazone in patients with insulin resistence without dia‑ betes mellitus. Circulation. 2017;135:1882-1893. 23. Vaccaro O, Masulli M, Nicolucci A, et al. Effects on their incidence of cardiovascular events of the addition of pioglitazonem versus sulfonylureas in patients with type 2 dia‑ betes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887-897. 24. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mor‑ tality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospec‑ tive cohort study using UK general practice research database. BMJ. 2009;339:b4731. 25. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective eva‑ luation of the outcome of second‑line, glucose‑lowering therapies in people with type 2 diabetes. J Clin Endocr Metab. 2012;97:4605- 4612. 26. Morgan CL, Inzucchi SE, Pulles J, et al. Impact of treatment with pioglitazone on stroke outcomes: a real world database analysis. Diabetes Obes Metab. 2018;20:2140- 2147. 27. Tseng CH. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Melli‑ tus: A Retrospective Cohort Analysis. J Clin Med. 2018;7:306. 28. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353-1362. 29. Karasek D. Vliv antidiabeticke lečby na kost nemocnych s DM 2. typu. Vnitř Lek. 2016;62:582-587. 30. SÚKL upozorňuje: pioglitazon a riziko kostních fraktur u žen. Farmakoterapeutické in‑ formace 5/2007. 31. Adil M, Khan RA, Ghosh P, et al. Pioglitazone and risk of bladder cancer in type 2 dia‑ betes mellitus patients: A systematic literature review and meta‑analysis of observational studies using real‑world data. Clin Epidemiol Glob Health. 2018;6:61-68. 32. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009. PMID: 34964831.
RkJQdWJsaXNoZXIy NDA4Mjc=